GATA2 and acute myeloid leukemia: In addition, recent studies demonstrate that GATA2 dosage controls the generation and maintenance of the hematopoietic stem cell, with overexpression promoting stemness and is more resistant to the standard AML chemotherapy agent doxorubicin [44].